Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect

International Journal of Pharmaceutics

Volumn 387, Issue 1-2, 2010, Pages 103-109

  Sugano, Kiyohiko ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Oral absorption; Particle size; Permeability; Unstirred water layer

Indexed keywords

CILOSTAZOL; DANAZOL; EFAVIRENZ; GRISEOFULVIN;

ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; INTESTINE TRANSIT TIME; MATHEMATICAL MODEL; MEMBRANE PERMEABILITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SIMULATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; MODELS, THEORETICAL; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WATER;

EID: 77649191330     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.12.014     Document Type: Article

References (49)

1. Ahmed I.S., Aboul-Einien M.H., Mohamed O.H., Farid S.F. Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states. Eur. J. Pharm. Sci. 2008, 35:219-225.
2. Allen A., Flemstroem G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am. J. Physiol. 2005, 288:C1-C19.
3. Amidon G.E., Higuchi W.I., Ho N.F.H. Theoretical and experimental studies of transport of micelle-solubilized solutes. J. Pharm. Sci. 1982, 71:77-84.
4. Atuma C., Strugala V., Allen A., Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. 2001, 280:G922-G929.
5. Avdeef A. Absorption and Drug Development 2003, Wiley-Interscience.
6. Avdeef A. High-throughput solubility, permeability, and the MAD PAMPA model. Pharmacokinetic Profiling in Drug Research 2006, Wiley-VCH, Zurich. B. Testa, S. Krämer, H. Wunderli-Allenspach, G. Folkers (Eds.).
7. Brocks D.R., Upward J.W., Georgiou P., Stelman G., Doyle E., Allen E., Wyld P., Dennis M.J. The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. Eur. J. Clin. Pharmacol. 1996, 51:303-308.
8. Chiou W.L., Riegelman S. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 1971, 60:1376-1380.
9. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 1996, 13:1838-1845.
10. Doyle-McCullough M., Smyth S.H., Moyes S.M., Carr K.E. Factors influencing intestinal microparticle uptake in vivo. Int. J. Pharm. 2007, 335:79-89.
11. Dressman J.B., Amidon G.L., Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 1985, 74:588-589.
12. Dressman J.B., Fleisher D. Mixing-tank model for predicting dissolution rate control or oral absorption. J. Pharm. Sci. 1986, 75:109-116.
13. Dressman J.B., Fleisher D., Amidon G.L. Physicochemical model for dose-dependent drug absorption. J. Pharm. Sci. 1984, 73:1274-1279.
14. Fagerholm U., Lennernaes H. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci. 1995, 3:247-253.
15. Florence A.T. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 1997, 14:259-266.
16. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
17. Gaumet M., Gurny R., Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur. J. Pharm. Sci. 2009, 36:465-473.
18. Glomme A., März J., Dressman J. Predicting the intestinal solubility of poorly soluble drugs. Pharmacokinetic Profiling in Drug Research 2006, 259-280. Wiley-VCH, Zurich. B. Testa, S. Krämer, H. Wunderli-Allenspach, G. Folkers (Eds.).
19. Haruta S., Iwasaki N., Ogawara K.-i., Higaki K., Kimura T. Absorption behavior of orally administered drugs in rats treated with propantheline. J. Pharm. Sci. 1998, 87:1081-1085.
20. Hodges G.M., Carr E.A., Hazzard R.A., Carr K.E. Uptake and translocation of microparticles in small intestine. Morphology and quantification of particle distribution. Dig. Dis. Sci. 1995, 40:967-975.
21. Jinno J.-I., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 2006, 111:56-64.
22. Johnson K.C. Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption. Drug Dev. Ind. Pharm. 2003, 29:833-842.
23. Johnson K.C., Swindell A.C. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 1996, 13:1795-1798.
24. Lennernaes H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37:1015-1051.
25. Limpanussorn J., Simon L., Dayan A.D. Transepithelial transport of large particles in rat: a new model for the quantitative study of particle uptake. J. Pharm. Pharmacol. 1998, 50:753-760.
26. Liversidge G.G., Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125:91-97.
27. Martin Y.C. A practitioner's perspective of the role of quantitative structure-activity analysis in medicinal chemistry. J. Med. Chem. 1981, 24:229-237.
28. Moyes S.M., Smyth S.H., Shipman A., Long S., Morris J.F., Carr K.E. Parameters influencing intestinal epithelial permeability and microparticle uptake in vitro. Int. J. Pharm. 2007, 337:133-141.
29. Norris D.A., Puri N., Sinko P.J. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 1998, 34:135-154.
30. Obata K., Sugano K., Saitoh R., Higashida A., Nabuchi Y., Machida M., Aso Y. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int. J. Pharm. 2005, 293:183-192.
31. Oh D.M., Curl R.L., Amidon G.L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. 1993, 10:264-270.
32. Okazaki A., Mano T., Sugano K. Theoretical dissolution model of poly-disperse drug particles in biorelevant media. J. Pharm. Sci. Technol. Jpn. 2007, 67. (meeting abstract and poster).
33. Okazaki A., Mano T., Sugano K. Theoretical dissolution model of poly-disperse drug particles in biorelevant media. J. Pharm. Sci. 2008, 97:1843-1852.
34. Oliver R.E., Jones A.F., Rowland M. What surface of the intestinal epithelium is effectively available to permeating drugs?. J. Pharm. Sci. 1998, 87:634-639.
35. Sawamoto T., Haruta S., Kurosaki Y., Higaki K., Kimura T. Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J. Pharm. Pharmacol. 1997, 49:450-457.
36. Smyth S.H., Feldhaus S., Schumacher U., Carr K.E. Uptake of inert microparticles in normal and immune deficient mice. Int. J. Pharm. 2008, 346:109-118.
37. Sugano K. Estimation of effective intestinal membrane permeability considering bile micelle solubilisation. Int. J. Pharm. 2009, 368:116-122.
38. Sugano K. Fraction of dose absorbed calculation: comparison between analytical solution based on one compartment steady state approximation and dynamic seven compartment model. CBI J. 2009, 9:75-93.
39. Sugano K. Introduction to computational oral absorption simulation. Expert. Opin. Drug Metab. Toxicol. 2009, 5:259-293.
40. Sugano K. Oral absorption simulation for poor solubility compounds. Chem. Biodivers. 2009, 6:2014-2029.
41. Sugano K. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population. Int. J. Pharm. 2009, 373:55-61.
42. Sugano K., Cucurull-Sanchez L., Bennett J. Membrane permeability-measurement and prediction in drug discovery. Hit to Lead Optimization. 2009, 117-143. Wiley-VCH, Weinheim. B. Faller, L. Urban (Eds.).
43. Sugano K., Okazaki A., Sugimoto S., Tavornvipas S., Omura A., Mano T. Solubility and dissolution profile assessment in drug discovery. Drug Metab. Pharmacokinet. 2007, 22:225-254.
44. Takano R., Furumoto K., Shiraki K., Takata N., Hayashi Y., Aso Y., Yamashita S. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm. Res. 2008, 25:2334-2344.
45. Takano R., Sugano K., Higashida A., Hayashi Y., Machida M., Aso Y., Yamashita S. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 2006, 23:1144-1156.
46. Yamashita S., Furubayashi T., Kataoka M., Sakane T., Sezaki H., Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 2000, 10:195-204.
47. Yu L.X. An integrated model for determining causes of poor oral drug absorption. Pharm. Res. 1999, 16:1883-1887.
48. Yu L.X., Amidon G.L. Characterization of small intestinal transit time distribution in humans. Int. J. Pharm. 1998, 171:157-163.
49. Yu L.X., Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 1999, 186:119-125.